AU5487199A - Novel esk potassium channel polypeptide and polynucleotide compositions - Google Patents

Novel esk potassium channel polypeptide and polynucleotide compositions

Info

Publication number
AU5487199A
AU5487199A AU54871/99A AU5487199A AU5487199A AU 5487199 A AU5487199 A AU 5487199A AU 54871/99 A AU54871/99 A AU 54871/99A AU 5487199 A AU5487199 A AU 5487199A AU 5487199 A AU5487199 A AU 5487199A
Authority
AU
Australia
Prior art keywords
esk
novel
potassium channel
channel polypeptide
polynucleotide compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54871/99A
Inventor
John R. Forsayeth
Byron B. Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Elan Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharmaceuticals LLC filed Critical Elan Pharmaceuticals LLC
Publication of AU5487199A publication Critical patent/AU5487199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU54871/99A 1998-08-14 1999-08-13 Novel esk potassium channel polypeptide and polynucleotide compositions Abandoned AU5487199A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9657098P 1998-08-14 1998-08-14
US60096570 1998-08-14
PCT/US1999/018556 WO2000009534A1 (en) 1998-08-14 1999-08-13 Novel esk potassium channel polypeptide and polynucleotide compositions

Publications (1)

Publication Number Publication Date
AU5487199A true AU5487199A (en) 2000-03-06

Family

ID=22257998

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54871/99A Abandoned AU5487199A (en) 1998-08-14 1999-08-13 Novel esk potassium channel polypeptide and polynucleotide compositions

Country Status (5)

Country Link
EP (1) EP1105406A4 (en)
JP (1) JP2003527818A (en)
AU (1) AU5487199A (en)
CA (1) CA2339406A1 (en)
WO (1) WO2000009534A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003041496A1 (en) * 2001-11-14 2003-05-22 Yamanouchi Pharmaceutical Co., Ltd. Transgenic animal
US8399663B2 (en) 2009-04-03 2013-03-19 Astellas Pharma Inc. Salt of 1,3,5-triazine-2,4,6-triamine derivative
JPWO2010137689A1 (en) * 2009-05-29 2012-11-15 アステラス製薬株式会社 Pharmaceutical composition for novel prevention and / or treatment of attention deficit / hyperactivity disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401629A (en) * 1990-08-07 1995-03-28 The Salk Institute Biotechnology/Industrial Associates, Inc. Assay methods and compositions useful for measuring the transduction of an intracellular signal
US5328830A (en) * 1992-09-08 1994-07-12 Miles Inc. Potassium channel modulators
US5599673A (en) * 1995-03-09 1997-02-04 University Of Utah Research Foundation Long QT syndrome genes
US5565483A (en) * 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
AU1982799A (en) * 1998-01-23 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel potassium channel protein

Also Published As

Publication number Publication date
WO2000009534A1 (en) 2000-02-24
JP2003527818A (en) 2003-09-24
EP1105406A4 (en) 2004-12-15
EP1105406A1 (en) 2001-06-13
CA2339406A1 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
AU8680698A (en) Polynucleotide compositions
AU3567099A (en) Analysis of polynucleotide sequence
HU9602086D0 (en) Glass composition
AU2349399A (en) R-lansoprazole compositions and methods
AU5203098A (en) Nail enamel composition
HU9602087D0 (en) Glass composition
AU8747498A (en) Food-preservative composition
AU5170599A (en) Water-repellent composition
AU5695198A (en) Nail enamel composition
AU3352397A (en) Additive composition
AU6076098A (en) Water-swellable compositions and sealants
HUP9600148A3 (en) Glass composition
AU8121998A (en) Composition
AU1077200A (en) Novel chimeric polypeptide
AU5770299A (en) Potassium channel polypeptide and polynucleotide compositions
AU5487199A (en) Novel esk potassium channel polypeptide and polynucleotide compositions
AUPP366198A0 (en) Anfo composition
AU1098499A (en) Emulsifier-lipid composition
AU2717399A (en) Two p domains potassium channel
AUPO430296A0 (en) Marking composition
AU8052798A (en) Polypeptide compositions that inhibit potassium channel activity and uses herefor
AU1649597A (en) Oximosilicon modified silicone sealant compositions
AU3900499A (en) (+)-hydroxyrisperidone compositions and methods
AU4334797A (en) Yeast composition
AU2648899A (en) Composition

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase